EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Preclinical Pharmacokinetics, ADME, and Drug-Drug Interaction Evaluation of S024, a Novel p38/MK2 Inhibitor for Rheumatoid Arthritis

Qianlei Ye, Wei Xing, Xuefeng Hu, Wenjuan Liu, Jigang Wu, Hailan Huang, Ying Xiao, Yanjun Hong

Drug Design, Development and Therapy · 2026

DOI: 10.2147/dddt.s591017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2026. Verfasst von Qianlei Ye und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences (Shenzhen), Sun Yat-Sen University, Shenzhen, People's Republic of China. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, p38 Mitogen-Activated Protein Kinases, Protein Serine-Threonine Kinases, Protein Kinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, Rheumatoidp38 Mitogen-Activated Protein KinasesProtein Serine-Threonine KinasesProtein Kinase InhibitorsAntirheumatic AgentsAnimalsHumansDogsRats, Sprague-DawleyRatsCaco-2 CellsDrug InteractionsMaleAdministration, OralDrug Evaluation, PreclinicalTissue Distribution

Stichwörter der Autor:innen

ADME profilingS024p38/MK2 inhibitorpharmacokineticsrheumatoid arthritis

Substanzen

p38 Mitogen-Activated Protein KinasesProtein Serine-Threonine KinasesProtein Kinase InhibitorsAntirheumatic Agents

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences (Shenzhen), Sun Yat-Sen University, Shenzhen, People's Republic of China.
  • Shenzhen Salubris Pharmaceuticals Co., Ltd, Shenzhen, Guangdong, People's Republic of China.

Zitieren

APA

Ye, Q., Xing, W., Hu, X., Liu, W., Wu, J., Huang, H., Xiao, Y., & Hong, Y. (2026). Preclinical Pharmacokinetics, ADME, and Drug-Drug Interaction Evaluation of S024, a Novel p38/MK2 Inhibitor for Rheumatoid Arthritis. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s591017

Vancouver

Ye Q, Xing W, Hu X, Liu W, Wu J, Huang H, et al. Preclinical Pharmacokinetics, ADME, and Drug-Drug Interaction Evaluation of S024, a Novel p38/MK2 Inhibitor for Rheumatoid Arthritis. Drug Design, Development and Therapy. 2026. doi:10.2147/dddt.s591017

BibTeX
@article{Ye2026,
  author = {Ye, Qianlei and Xing, Wei and Hu, Xuefeng and Liu, Wenjuan and Wu, Jigang and Huang, Hailan and Xiao, Ying and Hong, Yanjun},
  title = {Preclinical Pharmacokinetics, ADME, and Drug-Drug Interaction Evaluation of S024, a Novel p38/MK2 Inhibitor for Rheumatoid Arthritis},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  doi = {10.2147/dddt.s591017}
}
Kostenlos starten →